67 related articles for article (PubMed ID: 32227355)
1. Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment.
Grande E; Harvey RD; You B; Batlle JF; Galbraith H; Sarantopoulos J; Ramalingam SS; Mann H; So K; Johnson M; Vishwanathan K
J Pharmacol Exp Ther; 2019 May; 369(2):291-299. PubMed ID: 30872388
[TBL] [Abstract][Full Text] [Related]
2. Bidirectional pharmacokinetic drug interactions between olaparib and metformin.
Stanisławiak-Rudowicz J; Karbownik A; Szkutnik-Fiedler D; Otto F; Grabowski T; Wolc A; Grześkowiak E; Szałek E
Cancer Chemother Pharmacol; 2024 Jan; 93(1):79-88. PubMed ID: 37815561
[TBL] [Abstract][Full Text] [Related]
3. Improving olaparib exposure to optimize adverse effects management.
Sterlé M; Puszkiel A; Burlot C; Pereira E; Bellesoeur A; De Percin S; Beinse G; Fumet JD; Favier L; Niogret J; Blanchet B; Royer B; Bengrine-Lefevre L; Schmitt A
Ther Adv Med Oncol; 2024; 16():17588359241248328. PubMed ID: 38665845
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics.
Zeng Y; Arisa O; Peer CJ; Fojo A; Figg WD
Semin Oncol; 2024; 51(1-2):19-24. PubMed ID: 37880048
[TBL] [Abstract][Full Text] [Related]
5. Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment.
Gao D; Wang G; Wu H; Ren J
Sci Rep; 2023 Sep; 13(1):16027. PubMed ID: 37749178
[TBL] [Abstract][Full Text] [Related]
6. Olaparib and advanced ovarian cancer: Summary of the past and looking into the future.
Maiorano BA; Maiorano MFP; Maiello E
Front Pharmacol; 2023; 14():1162665. PubMed ID: 37153769
[TBL] [Abstract][Full Text] [Related]
7. Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis.
Cheng JM; Canzoniero J; Lee S; Soni S; Mangini N; Santa-Maria CA
Breast Cancer Res Treat; 2023 Jun; 199(2):389-397. PubMed ID: 37002487
[TBL] [Abstract][Full Text] [Related]
8. Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment.
Zhao D; Long X; Wang J
Drug Des Devel Ther; 2022; 16():3947-3955. PubMed ID: 36405648
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.
Bruin MAC; Sonke GS; Beijnen JH; Huitema ADR
Clin Pharmacokinet; 2022 Dec; 61(12):1649-1675. PubMed ID: 36219340
[TBL] [Abstract][Full Text] [Related]
10. PARP Inhibitors for Breast Cancer: Germline
Menezes MCS; Raheem F; Mina L; Ernst B; Batalini F
Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077867
[TBL] [Abstract][Full Text] [Related]
11. Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations.
Yang DZ; Alhadab A; Parivar K; Wang DD; Elmeliegy M
Clin Pharmacol Ther; 2022 Oct; 112(4):782-790. PubMed ID: 34870845
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.
Grechko N; Skarbova V; Tomaszewska-Kiecana M; Ramlau R; Centkowski P; Drew Y; Dziadziuszko R; Zemanova M; Beltman J; Nash E; Habeck J; Liao M; Xiao J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):259-270. PubMed ID: 33909097
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
Rolfo C; de Vos-Geelen J; Isambert N; Molife LR; Schellens JHM; De Grève J; Dirix L; Grundtvig-Sørensen P; Jerusalem G; Leunen K; Mau-Sørensen M; Plummer R; Learoyd M; Bannister W; Fielding A; Ravaud A
Clin Pharmacokinet; 2019 Sep; 58(9):1165-1174. PubMed ID: 30877569
[TBL] [Abstract][Full Text] [Related]
14. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
Plummer R; Swaisland H; Leunen K; van Herpen CM; Jerusalem G; De Grève J; Lolkema MP; Soetekouw P; Mau-Sørensen M; Nielsen D; Spicer J; Fielding A; So K; Bannister W; Molife LR
Cancer Chemother Pharmacol; 2015 Oct; 76(4):723-9. PubMed ID: 26242220
[TBL] [Abstract][Full Text] [Related]
15. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
[TBL] [Abstract][Full Text] [Related]
16. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
17. Safety evaluation of olaparib for treating ovarian cancer.
Lheureux S; Bowering V; Karakasis K; Oza AM
Expert Opin Drug Saf; 2015 Aug; 14(8):1305-16. PubMed ID: 26051946
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment.
Rolfo C; Isambert N; Italiano A; Molife LR; Schellens JHM; Blay JY; Decaens T; Kristeleit R; Rosmorduc O; Demlova R; Lee MA; Ravaud A; Kopeckova K; Learoyd M; Bannister W; Locker G; de Vos-Geelen J
Br J Clin Pharmacol; 2020 Sep; 86(9):1807-1818. PubMed ID: 32227355
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
